Heart failure monitor最新文献

Back to the future? 回到未来?

Heart failure monitor Pub Date : 2021-10-27 DOI: 10.7748/ns.2.10.42.s97

A. Clark

引用次数: 0

State-of-the-Art Prevention of Heart Failure: Maladaptive versus Adaptive Hypertrophy. 最先进的心力衰竭预防:不适应与适应性肥厚。

Heart failure monitor Pub Date : 2008-02-01

Gianluigi Condorelli, Michael Vg Latronico, Mario Condorelli

引用次数: 0

Neuregulin-1 and its potential role in the control of cardiac function. 神经调节蛋白-1及其在心功能控制中的潜在作用。

Heart failure monitor Pub Date : 2008-02-01

Katrien Lemmens, Kris Doggen, Gilles W De Keulenaer

{"title":"Neuregulin-1 and its potential role in the control of cardiac function.","authors":"Katrien Lemmens, Kris Doggen, Gilles W De Keulenaer","doi":"","DOIUrl":"","url":null,"abstract":"The rapidly evolving insights into the protective and modulatory function of neuregulin-1 (NRG-1) in the adult heart are discussed in this review. The actions of NRG-1 in the adult heart have begun to be elucidated following the unexpected clinical observation that trastuzumab can cause ventricular dysfunction and increases the risk of cardiomyopathy induced by anthracyclines. Trastuzumab is an inhibitory antibody against the NRG receptor erythroblastic leukemia viral oncogene homolog 2 (ErbB2) and is used in the treatment of breast cancer. In vitro studies have demonstrated that NRG-1 promotes growth and survival of isolated cardiomyocytes. Ventricular dysfunction following anti-ErbB2 treatment was initially explained by a loss of ErbB2-dependent cell survival pathways in the heart. However, in vivo studies in genetically modified mice did not uniformly confirm this finding. More recent studies have revealed that NRG-1 counterbalances the adrenergic inotropic response of the adult myocardium through an obligatory interaction with the muscarinic cholinergic system. In addition, it was demonstrated that cardiac NRG-1 synthesis and release from the cardiac endothelium, the principal source of NRG-1 in the heart, is dynamically controlled by neurohormonal and biomechanical stimuli, allowing adaptive tuning of ErbB signaling during cardiovascular stress. Cardiac NRG-1 is beginning to emerge as a cardioprotective factor implicated in the physiological regulation of myocardial performance and sympathovagal balances. Cardiac NRG-1/ErbB signaling has implications for the treatment of both cancer and heart failure. As novel ErbB inhibitors are currently being tested in broader oncological indications, there is a need to better understand their cardiovascular side effects. It is possible that pharmacological activation of ErbB signaling is an indirect, beneficial effect of the drugs currently used in heart failure, and this could be a promising therapeutic approach for prevention or reversal of myocardial dysfunction. Heart Fail Monit 2008;5(4):119-24.","PeriodicalId":84857,"journal":{"name":"Heart failure monitor","volume":"5 4","pages":"119-24"},"PeriodicalIF":0.0,"publicationDate":"2008-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27263818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential benefits of treatment of sleep apnea in heart failure. 治疗心力衰竭患者睡眠呼吸暂停的潜在益处。

Heart failure monitor Pub Date : 2008-02-01

Stephan Steiner, Per O Schueller, Marcus G Hennersdorf, Bodo E Strauer

引用次数: 0

Diuretics - a panacea for acute heart failure? Different formulations, doses, and combinations. 利尿剂——治疗急性心力衰竭的灵丹妙药?不同的配方、剂量和组合。

Heart failure monitor Pub Date : 2008-01-01

Olga Milo Cotter, Asha N Sasimangalam, Pradeep S Arumugham, Edo Kaluski, Beth Weatherley, Gad Cotter

引用次数: 0

Women, men and heart failure: a review. 女性、男性与心力衰竭:综述。

Heart failure monitor Pub Date : 2008-01-01

Annika Rosengren, Paul Hauptman

{"title":"Women, men and heart failure: a review.","authors":"Annika Rosengren, Paul Hauptman","doi":"","DOIUrl":"","url":null,"abstract":"Chronic heart failure (HF) is a major cause of morbidity and mortality, and is the reason for more than one in five of all hospital admissions in patients aged >65 years. Major advances in the diagnosis and treatment of HF over the last two decades have proven effective in reducing morbidity and mortality among both men and women, but with less improvement for women and elderly patients. Women and men with HF differ in several respects. Women tend to be older and more often hypertensive, but are less likely to demonstrate any clinical evidence of coronary heart disease (CHD) and more often have preserved ventricular function. Conversely, hypertension plays a greater role in the development of HF in women than in men. Sex differences in systolic and diastolic function in patients with hypertension have been demonstrated. Although men have higher incidence of HF at all ages, lifetime risk is similar in men and women because women live longer. Intervention studies have included far more men than women but in patients with reduced ventricular function there is no evidence to suggest that women benefit less than men from evidence-based treatments, and current guidelines do not differentiate between men and women. There is no consistent recent evidence that women receive poorer quality of care than men. Women with HF have better survival rates than men, which may be due to better systolic function or less CHD among women; however, mortality rates for HF are still very high regardless of sex. As most trials have been targeted towards patients with left ventricular systolic dysfunction, which is less typical for women than for men with HF, more research is needed to help define treatment aimed at improving prognosis for patients with HF and preserved systolic function. In light of these differences and ongoing uncertainties, future European guidelines should incorporate gender issues. Heart Fail Monit 2008;6(1):34-40.","PeriodicalId":84857,"journal":{"name":"Heart failure monitor","volume":"6 1","pages":"34-40"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37434874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Congenital heart disease and heart failure. 先天性心脏病和心力衰竭。

Heart failure monitor Pub Date : 2008-01-01

Wei Li, Michael Y Henein

{"title":"Congenital heart disease and heart failure.","authors":"Wei Li, Michael Y Henein","doi":"","DOIUrl":"","url":null,"abstract":"The syndrome of heart failure in adult non-congenital heart disease patients includes myocardial disease and ventricular dysfunction. In the presence of congenital abnormalities the cause of heart failure is often multi-factorial and can be a result of the underlying anomaly, surgical intervention, or ventricular dysfunction. Despite the possible clinical similarities, the two conditions are fundamentally different. In congenital heart disease the neurohormonal system is already abnormal even in the absence of clinical manifestations of heart failure and, in many cases, exercise intolerance is related to cyanosis. The approach to heart failure management in the two etiologies might be similar. Preventative attempts to preserve ventricular function in coronary or valve disease parallels early reparative therapy in congenital heart disease Pharmacological therapy is common for the two conditions, despite the limited number of evidence-based recommendations for congenital diseases. In drug-resistant patients, cardiac electrical resynchronization is an established therapy for treating ventricular asynchrony in non-congenital heart failure sufferers, but has only recently been adopted in selected congenital cases. Due to this, congenital heart disease patients are managed in highly specialized unites in close cooperation with cardiologists and surgeons. The ideal follow-up protocol for such patients remains to be determined, particularly in those individuals with subclinical signs of residual cardiac dysfunction. Heart Fail Monit 2008;6(1):2-8.","PeriodicalId":84857,"journal":{"name":"Heart failure monitor","volume":"6 1","pages":"2-8"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37434870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pharmacological rationale behind polypharmacy in heart failure. 心力衰竭多重用药背后的药理学原理。

Heart failure monitor Pub Date : 2008-01-01

Kai Kappert, Heike Kusserow, Thomas Unger

引用次数: 0

Anemia and erythropoietin in heart failure. 心力衰竭中的贫血和促红细胞生成素。

Heart failure monitor Pub Date : 2008-01-01

Peter van der Meer, Erik Lipsic, Wiek H van Gilst, Dirk J van Veldhuisen

引用次数: 0

Should we inhibit angiotensin-converting enzymes in acute heart failure? 急性心力衰竭时是否应该抑制血管紧张素转换酶?

Heart failure monitor Pub Date : 2007-01-01

Nathan W D Lamond, Jonathan G Howlett

引用次数: 0